HRB-Clinical Research Facility, National University of Ireland Galway, Galway, Ireland; Galway University Hospital, Newcastle Road, Galway, Ireland.
HRB-Clinical Research Facility, National University of Ireland Galway, Galway, Ireland; Galway University Hospital, Newcastle Road, Galway, Ireland; Wellcome Trust - HRB, Irish Clinical Academic Training, Dublin, Ireland.
Am J Med. 2020 Dec;133(12):1471-1478.e4. doi: 10.1016/j.amjmed.2020.05.028. Epub 2020 Jun 27.
Guidelines recommend increased salt intake as a first-line recommendation in the management of symptomatic orthostatic hypotension and recurrent syncope. There have been no systematic reviews of this intervention. We sought to summarize the evidence for increased salt intake in patients with orthostatic intolerance syndromes.
We conducted a systematic review and meta-analysis of studies in PubMed, EMBASE, and CINAHL. Interventional studies that increased salt intake in individuals with orthostatic intolerance syndromes were included. Primary outcome measures included incidence of falls and injuries, and rates of syncope and presyncope. Secondary outcome measures included other orthostatic intolerance symptoms, blood pressure, and heart rate.
A total of 14 studies were eligible, including participants with orthostatic hypotension, syncope, postural orthostatic tachycardia syndrome, and idiopathic orthostatic tachycardia (n = 391). Mean age was 35.6 (± 15) years. All studies were small and short-term (<60 mins-90 days). No study reported on the effect of increased salt intake on falls or injuries. Meta-analysis demonstrated that during head-up tilt, mean time to presyncope with salt intake increased by 1.57 minutes (95% confidence interval [CI], 1.26-1.88), mean systolic blood pressure increased by 12.27 mm Hg (95% CI, 10.86-13.68), and mean heart rate decreased by -3.97 beats per minute (95% CI, -4.08 to -3.86), compared with control. Increased salt increased supine blood pressure by 1.03 mm Hg (95% CI, 0.81 to 1.25). Increased salt intake resulted in an improvement or resolution of symptoms in 62.3% (95% CI, 51.6 to 72.6) of participants in short-term follow-up studies (mean follow-up of 44.3 days, 6 studies; n=91). Methodological quality of studies were low with high statistical heterogeneity in all meta-analyses.
Our meta-analysis provides low-quality evidence of a short-term improvement in orthostatic intolerance with increased salt intake. There were no clinical trials demonstrating the efficacy and safety of increased salt intake on long-term clinical outcomes. Overall, there is a paucity of clinical trial evidence to support a cornerstone recommendation in the management of orthostatic intolerance syndromes.
指南建议增加盐摄入量作为治疗有症状直立性低血压和反复晕厥的一线推荐。目前尚未对这种干预措施进行系统评价。我们旨在总结盐摄入增加在直立不耐受综合征患者中的证据。
我们对 PubMed、EMBASE 和 CINAHL 中的研究进行了系统评价和荟萃分析。纳入了增加直立不耐受综合征患者盐摄入量的干预性研究。主要结局指标包括跌倒和损伤的发生率,以及晕厥和先兆晕厥的发生率。次要结局指标包括其他直立不耐受症状、血压和心率。
共有 14 项研究符合条件,包括体位性低血压、晕厥、姿势性心动过速综合征和特发性直立性心动过速患者(n=391)。平均年龄为 35.6(±15)岁。所有研究均较小且短期(<60 分钟-90 天)。没有研究报告盐摄入增加对跌倒或损伤的影响。荟萃分析表明,在头高位倾斜期间,盐摄入时先兆晕厥的平均时间增加了 1.57 分钟(95%置信区间[CI],1.26-1.88),平均收缩压增加了 12.27mmHg(95%CI,10.86-13.68),平均心率每分钟下降了-3.97 次(95%CI,-4.08 至-3.86),与对照组相比。盐摄入使仰卧位血压升高 1.03mmHg(95%CI,0.81 至 1.25)。短期随访研究(平均随访 44.3 天,6 项研究;n=91)中,62.3%(95%CI,51.6 至 72.6)的参与者症状得到改善或缓解。所有荟萃分析的研究方法质量均较低,且具有高度统计学异质性。
我们的荟萃分析提供了低质量证据,表明盐摄入增加可在短期内改善直立不耐受。没有临床试验证明盐摄入对长期临床结局的疗效和安全性。总体而言,支持直立不耐受综合征管理中基石推荐的临床试验证据很少。